CDER organizational changes
This article was originally published in The Tan Sheet
Executive Summary
Office of Review Management renamed Office of New Drugs, effective Jan. 13. As of Jan. 1, newly created Office of Pharmacoepidemiology & Statistical Science (OPaSS) will include Office of Biostatistics and Office of Drug Safety (formerly Office of Post-Marketing & Drug Risk Assessment). ODS now houses MedWatch program, medication guides function. OPaSS is headed by Paul Seligman, MD (1"The Tan Sheet" Nov. 12, 2001, p. 16)...
You may also be interested in...
CDER Deputy Director Galson To Head Drug Center For Several Months
Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, will serve as the center's acting director for the next several months
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.